Bruker Corp
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.1 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 95.28% +0.15pp
- Institutions
- 509 +13
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-08-15
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Frank Laukien | Chairperson & CEO | 26.47% |
| Joerg Laukien | Former Director | 4.92% |
| Juergen Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | 0.10% |
| Mark Munch | Corporate Executive VP & President of Bruker Nano Group | 0.06% |
| Richard Packer | Director | 0.06% |
| Gerald Herman | Chief Financial Officer | 0.04% |
| William Linton | Independent Director | 0.04% |
| John Ornell | Independent Director | 0.02% |
| Robert Rosenthal | Independent Director | 0.02% |
| Falko Busse | Former President of Bruker BioSpin Group | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Mark Munch | Corporate Executive VP & President of Bruker Nano Group | Derivative Exercise and Sale | -2,000 | $22.19–52.87 |
| 2026-08-16 | Wolfgang Pusch | -- | Open Market Disposition | -3,473 | $56.90 |
| 2026-08-14 | Frank Laukien | Chairperson & CEO | Sale to Issuer | -4,760 | $57.70 |
| 2026-08-14 | Frank Laukien | Chairperson & CEO | Other Acquisition | +29,463 | -- |
| 2026-08-14 | Frank Laukien | Chairperson & CEO | Other Derivative Acquisition | +71,651 | $63.47 |
| 2026-08-14 | Mark Munch | Corporate Executive VP & President of Bruker Nano Group | Sale to Issuer | -2,984 | $57.70 |
| 2026-08-14 | Mark Munch | Corporate Executive VP & President of Bruker Nano Group | Other Acquisition | +14,443 | -- |
| 2026-08-14 | Mark Munch | Corporate Executive VP & President of Bruker Nano Group | Other Derivative Acquisition | +11,708 | $57.70 |
| 2026-08-14 | Gerald Herman | Chief Financial Officer | Sale to Issuer | -2,724 | $57.70 |
| 2026-08-14 | Gerald Herman | Chief Financial Officer | Other Acquisition | +15,794 | -- |
| 2026-08-14 | Gerald Herman | Chief Financial Officer | Other Derivative Acquisition | +12,803 | $63.47 |
| 2026-08-14 | Burkhard Prause | President and CEO of Bruker Energy & Supercon Technologies, Inc. | Other Acquisition | +3,303 | -- |
| 2026-08-14 | Burkhard Prause | President and CEO of Bruker Energy & Supercon Technologies, Inc. | Other Derivative Acquisition | +2,678 | $57.70 |
| 2026-08-14 | Juergen Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | Other Acquisition | +16,898 | -- |
| 2026-08-14 | Juergen Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | Other Derivative Acquisition | +13,698 | $57.70 |
| 2026-08-14 | Thomas Bures | Chief Accounting Officer | Other Acquisition | +4,035 | -- |
| 2026-08-14 | Wolfgang Pusch | -- | Other Acquisition | +3,120 | -- |
| 2026-08-14 | Wolfgang Pusch | -- | Other Derivative Acquisition | +2,529 | $57.70 |
| 2026-08-13 | Mark Munch | Corporate Executive VP & President of Bruker Nano Group | Derivative Exercise and Sale | -2,000 | $22.19–57.60 |
| 2026-08-10 | Frank Laukien | Chairperson & CEO | Sale to Issuer | -4,838 | $57.02 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.
Bruker Corp discussion 0 comments